BASINGSTOKE, England, March 3 (UPI) -- Shire said Friday it filed a lawsuit in U.S. federal court claiming Teva infringed upon Shire's patents on Adderall XR.
The suit, which was filed in the U.S. District Court for the Eastern District of Pennsylvania, stems from an abbreviated new drug application Teva filed for generic versions of Adderall XR, Shire's attention deficit hyperactivity disorder medication.
Shire said Teva provided notice that it would try to market its generic formulation prior to the expiration of two of Shire's patents that run until 2018.
"The lawsuit alleges that all of Teva's generic strengths infringe the patents in suit," Shire said in a statement.
Shire said under Hatch-Waxman there will be a 30-month stay of FDA approval of Teva's 25 mg dosage of its generic formulation.
